Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 1.00 |
| ▸ | TTR | P02766 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CA12 | O43570 | 2/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 1.00 |
| ▸ | CA4 | P22748 | 2/20 | 1.00 |
| ▸ | PSMB5 | P28074 | 2/20 | 1.00 |
| ▸ | CA7 | P43166 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | SHBG | P04278 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naringenin SCHEMBL20570 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Naringenin SCHEMBL25894738 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Naringenin SCHEMBL20571 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Naringenin SCHEMBL1048136 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Naringenin SCHEMBL29351357 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Naringenin SCHEMBL30785808 | 0.99 | CYP19A1 (0.97) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Naringenin SCHEMBL30377739 | 0.99 | CYP19A1 (0.97) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Naringenin SCHEMBL30267460 | 0.99 | CYP19A1 (0.97) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Naringenin SCHEMBL3814677 | 0.99 | CYP19A1 (0.97) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Naringenin SCHEMBL30785807 | 0.99 | CYP19A1 (0.97) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108366597-B | Substance mixture | 西姆莱斯有限公司 | 2022-09-02 | — | — | CN | claimed |
| CN-114230541-A | Manual naringenin splitting method and absolute configuration determining method | 浙江省柑橘研究所 | 2022-03-25 | — | — | CN | claimed |
| US-12635718-B2 | Flavanone derivatives and their use as sweetness enhancers | FIRMENICH SA (CH) | 2026-05-26 | — | — | US | disclosed |
| WO-2025215165-A1 | LIQUID ANTIMICROBIAL COMPOSITION | MINASOLVE SAS (FR) | 2025-10-16 | — | — | WO | disclosed |
| CN-119587671-A | Traditional Chinese medicine composition for treating digestive tract polyp and digestive tract tumor as well as preparation and application thereof | 中国中医科学院望京医院(中国中医科学院骨伤科研究所) | 2025-03-11 | — | — | CN | disclosed |
| WO-2025043394-A1 | KIT FOR FORMING SUPRAMOLECULAR SELF-ASSEMBLY COMPLEX AND USE THEREOF | 北京睿创康泰医药研究院有限公司 | 2025-03-06 | — | — | WO | disclosed |
| CN-114364265-B | Flavanone derivatives and their use as sweetness enhancers | 弗门尼舍有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-11814563-B2 | Bioreachable chiral dopants for liquid crystal applications | ZYMERGEN INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814563-B2 | Bioreachable chiral dopants for liquid crystal applications | ZYMERGEN INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814563-B2 | Bioreachable chiral dopants for liquid crystal applications | ZYMERGEN INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230136465-A1 | PLANT-BASED CHICKEN FLAVORING AGENT COMPOSITION | NotCo Delaware AI, LLC | 2023-05-04 | — | — | US | disclosed |
| CN-114364265-A | Flavanone derivatives and their use as sweetness enhancers | 弗门尼舍有限公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-114230541-A | Manual naringenin splitting method and absolute configuration determining method | 浙江省柑橘研究所 | 2022-03-25 | — | — | CN | disclosed |
| CN-114230541-A | Manual naringenin splitting method and absolute configuration determining method | 浙江省柑橘研究所 | 2022-03-25 | — | — | CN | disclosed |
| US-20220025267-A1 | BIOREACHABLE CHIRAL DOPANTS FOR LIQUID CRYSTAL APPLICATIONS | ZYMERGEN ACQUISITION SUB, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20220025267-A1 | BIOREACHABLE CHIRAL DOPANTS FOR LIQUID CRYSTAL APPLICATIONS | ZYMERGEN ACQUISITION SUB, INC. | 2022-01-27 | — | — | US | disclosed |
| WO-2020159620-A9 | BIOREACHABLE CHIRAL DOPANTS FOR LIQUID CRYSTAL APPLICATIONS | ZYMERGEN INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| CN-108967756-A | It is a kind of can help but also defaecation drinks | 郑州国手生物科技有限公司 | 2018-12-11 | — | — | CN | disclosed |
| CN-108271959-A | The super drinks made of tomato, hawthorn, jujube, mulberry fruit | 郑州国手生物科技有限公司 | 2018-07-13 | — | — | CN | disclosed |
| US-9155792-B2 | RecA inhibitors with antibiotic activity, compositions and methods of use | TRUSTEES OF BOSTON UNIVERSITY (US) | 2015-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12635718-B2 | Flavanone derivatives and their use as sweetness enhancers | TAS2R10, TAS2R20, TAS2R7 | CYP19A1 2593/4885CYP3A4 3109/4885CYP1A1 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.